GlassScriptPhysician profile
Patrick Nakashima-Moran
NPI 1558743138
$5,031.16
in general payments reported to CMS, 2019-2025
29 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $518 · 2021: $1,062 · 2022: $740 · 2023: $802 · 2024: $733 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $770.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $622.19 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $562.42 | 2021-2025 | |
| Novo Nordisk INC | $477.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $312.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $266.29 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $185.01 | 2021-2025 | Spravato |
| Pfizer INC. | $183.03 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.04 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $145.08 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $140.12 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $133.21 | 2019-2024 | |
| Amgen INC. | $131.51 | 2021-2025 | Evenity, Prolia, Otezla |
| Phathom Pharmaceuticals, INC. | $125.27 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $104.44 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $100.10 | 2019-2023 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.74 | 2019-2023 | Xifaxan |
| Dexcom, INC. | $81.59 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $73.36 | 2019-2025 | Freestyle Libre 3 |
| Allergan, INC. | $67.28 | 2019-2020 | |
| Exact Sciences Corporation | $62.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $45.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $42.63 | 2022 | |
| Sanofi Pasteur INC. | $38.27 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.94 | 2022 | |
| Esperion Therapeutics, INC. | $25.86 | 2021 | |
| Sumitomo Pharma America, INC. | $21.43 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $20.86 | 2023 | Gvoke Hypopen |
| Cmp Pharma, INC. | $14.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Nakashima-Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.